Durability of the Mitroflow Pericardial Prosthesis: Influence of Patient–Prosthesis Mismatch and New Anticalcification Treatment (original) (raw)

The Thoracic and Cardiovascular Surgeon

Abstract

Background The Mitroflow pericardial bioprosthesis (MPB) has been recently associated with a high incidence of early structural failures, questioning its validity as cardiac valve substitute. We have therefore reviewed our experience with this device. Materials and Methods A total of 398 patients with a mean age of 75 ± 7 years (58% above the age of 75 years) had aortic valve replacement with a Mitroflow prosthesis (2005–2015). Most patients had calcific aortic stenosis (86%) and were in sinus rhythm (89%). Mean EuroSCORE II was 5.5 ± 6.2. Mean follow-up was 4 ± 2 years (range: 4 months to 10 years), which was 100% complete. Results Hospital mortality was 6.5%; at discharge, 25% of patients had a moderate patient–prosthesis mismatch and none had a severe mismatch. Cumulative incidence of structural valve deterioration in the entire series was 2% (95% confidence interval [CI]: 1–4) at 5 years and 7% (95% CI: 4–14) at 8 years. Significant factors influencing MPB durability were age ≤ ...

Giacomo Ravenni hasn't uploaded this paper.

Let Giacomo know you want this paper to be uploaded.

Ask for this paper to be uploaded.